BP to update on cost-cutting progress as Elliot increases pressure, FT reports
Elliott wants BP CEO Murray Auchincloss to add another $5 billion of cost savings to the $4 billion-$5 billion in reductions by 2027 he announced in February from a 2023 baseline, the FT report said.
Reuters could not immediately verify the report. BP and Elliott did not immediately respond to a request for comment.
The hedge fund has "identified tens of thousands of BP support staff globally" as an example of the cost base, the report added.
BP has already cut $750 million of costs towards its target in 2024, and is looking to reach its cost savings target through job cuts, divestment and streamlining supply chains, the FT report said.
Reuters reported in April that the activist investor would like BP to cut its spending to around $12 billion a year, down from a current range of $13 billion-$15 billion, through to 2027, and deepen its cost cuts, especially on administrative expenses.
Elliott, which holds a stake of little more than 5% in BP, also wants the oil major to replace its strategy chief and create separate units for upstream and downstream activities to improve accountability.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
2 hours ago
- Reuters
Trump's Fed pick, Bank of England's 'hawkish' cut weigh on dollar
SINGAPORE, Aug 8 (Reuters) - The dollar was under pressure on Friday and was on course for a weekly fall as U.S. President Donald Trump's temporary choice for a fill-in Federal Reserve Governor stoked expectations for a dovish pick to replace chair Jerome Powell when his term ends. Sterling hovered near a two-week high, clinging to Thursday's sharp gains as the Bank of England cut interest rates but only after a narrow 5-4 vote, which showed the central bank's easing bias lacked conviction. Meanwhile, Trump's decision to nominate Council of Economic Advisers Chairman Stephen Miran to serve on a newly vacant seat at the Fed, while White House seeks a permanent addition, weighed on the dollar. Miran replaces Governor Adriana Kugler following her surprise resignation last week. "While we expect Miran to advocate for lower interest rates, we do not consider he will push the FOMC to cut the Funds rate if the data does not support a cut," said Joseph Capurso, head of international economics at the Commonwealth Bank of Australia. "Depending on the president's perception of his performance, he may also be a contender to replace Chair Powell when his term ends in May." Trump has repeatedly criticised Powell for not cutting interest rates, and while he has backed off threats to oust Powell before his term ends on May 15, has accelerated the search for a replacement. Fed Governor Christopher Waller is emerging as a top candidate to be the next chair, Bloomberg news reported on Thursday. Against a basket of peers, the dollar is down nearly 0.7% on the week so far as concerns over softening U.S. economic momentum, especially in the labour market, boosted hopes of Fed rate cuts. The dollar index was last at 98.04 in early trading on Friday. The Japanese yen was flat at 147.07 per dollar. Adam Grotzinger, senior fixed income portfolio manager at Neuberger Berman, expects four consecutive rate cuts from the Fed totalling 100 basis points, starting later this year and finishing early next year. "When we're looking at economic data, don't be surprised by softer prints coming in on the economy in Q3," Grotzinger said. "That said, for the full year we expect kind of an okay growth, but slower than the last couple years." Traders are pricing in a 93% chance of a rate cut in September with at least two rate cuts priced in by the end of the year. Atlanta Fed president Raphael Bostic said on Thursday that while risks to the job market have increased, it remains too soon to commit to rate cuts with more data lined up ahead of the Fed's policy review scheduled for September 16-17. The BOE's split vote on Thursday showed policymakers remained concerned about still high inflation, even as it cut rates. The pound was nearly flat at $1.3439 on Friday, holding the previous session's gains and on course to clock its best weekly performance since late June. The vote-split in the BoE meeting "implies one of the most hawkish versions of a 25bp cut that reasonable could have been expected," analysts at Goldman Sachs said. Elsewhere, the euro was perched near a two-week high as investors found comfort in the prospect of talks between the U.S. and Russia aimed at ending the war in Ukraine. Russian President Vladimir Putin and U.S. President Donald Trump will meet in the coming days, Kremlin aide Yuri Ushakov said on Thursday. This would mark the first summit between leaders of the U.S. and Russia since June 2021. With the Kremlin announcing summit plans, "geopolitics are in the spotlight and likely to be the major driver of FX markets heading into the weekend," analysts at ANZ wrote in a Friday note.
Reuters
2 hours ago
- Reuters
India's IOC buys 5 million barrels of crude for Oct delivery, sources say
NEW DELHI/SINGAPORE, Aug 8 (Reuters) - Indian Oil Corp ( opens new tab, the country's largest refiner, has bought 5 million barrels of crude for October delivery, trade sources said, continuing its buying spree amid pressure from U.S. President Donald Trump to halt Russian purchases. IOC bought 2 million barrels of U.S. Mars crude, 2 million barrels of Brazilian grades and another 1 million barrels of Libyan crude on a delivered basis via a tender, the sources said. BP (BP.L), opens new tab sold the high-sulphur Mars crude cargo at $1.5-$2 a barrel above September Dubai quotes, they added. European trader Petraco sold the 1 million barrels of Libyan Sarir and Mesla crude and Totsa, the trading arm of TotalEnergies ( opens new tab, sold the 2 million barrels of Brazilian Sepia and Sururu crude, the sources said.
Reuters
2 hours ago
- Reuters
CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech
Aug 7 (Reuters) - German drugmaker CureVac ( opens new tab and GSK (GSK.L), opens new tab reached an agreement with BioNTech ( opens new tab and Pfizer (PFE.N), opens new tab on Thursday to resolve a years-long patent dispute related to mRNA-based COVID-19 vaccines, CureVac said. As part of the settlement, CureVac and GSK will receive a combined payment of $740 million and single-digit royalties on sales of COVID-19 vaccines in the U.S. going forward. CureVac will also grant BioNTech and Pfizer a non-exclusive license to manufacture, use, import and sell mRNA-based COVID-19 and influenza products in the U.S. The settlement comes after BioNTech agreed to acquire its domestic peer CureVac in a $1.25 billion all-stock deal in June. Three years ago, CureVac had filed a patent lawsuit against BioNTech over its use of mRNA technology, seeking fair compensation from the company and two of its subsidiaries for infringement of its intellectual property rights. CureVac had said that its claim to intellectual property rights was based on more than two decades of work on mRNA technology, some of which was used by BioNTech and Pfizer for the development and sale of their Comirnaty coronavirus vaccine. CureVac's efforts to develop an mRNA-based COVID-19 vaccine did not come to fruition during the pandemic, whereas BioNTech and its partner Pfizer chalked up more than $40 billion in combined vaccine sales in 2021 and 2022.
